Explore /
Poster
/ A phase I dose-escalation study evaluating the effects of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with select relapsed or refractory hematologic malignancies.

A phase I dose-escalation study evaluating the effects of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with select relapsed or refractory hematologic malignancies.

Authors

Alexander M. Lesokhin

Memorial Sloan-Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY

Alexander M. Lesokhin , Martin Gutierrez , Ahmad Sami Halwani , Stephen Maxted Ansell , Philippe Armand , Ivan Borrello , Zdenka E Segota , Adam D. Cohen , Moshe Talpaz , Deepika Cattry , Tracy Turner , Maria Mezes , Christina Hartman , Ashok Kumar Gupta , Su Young Kim , Jon M. Wigginton , John Timmerman

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics - Immunotherapy

Track

Developmental Therapeutics

Sub Track

Immunotherapy and Biologic Therapy

Clinical Trial Registration Number

NCT01592370

Citation

J Clin Oncol 31, 2013 (suppl; abstr TPS3113)

DOI

10.1200/jco.2013.31.15_suppl.tps3113

Abstract #

TPS3113

Poster Bd #

22H

Abstract Disclosures

Similar Posters

Poster

2018 ASCO Annual Meeting

$A phase 1, open label, dose escalation study of MGD009, a humanized B7-H3 x CD3 DART protein, in combination with MGA012, an anti-PD-1 antibody, in patients with relapsed or refractory B7-H3-expressing tumors.$